WALTHAM, Mass.--(BUSINESS WIRE)--Jun 5, 2023--
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230605005016/en/
The Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer offers accurate and precise quantitation in proteomics laboratories with faster throughput, deeper coverage and higher sensitivity than the current state-of-the-art. (Photo: Business Wire)
“Continuing our strong track record of high impact innovation, this remarkable advancement will enable key scientific breakthroughs that will allow our customers to develop new, targeted therapies for a range of diseases,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We are proud to launch this cutting-edge technology as it will meaningfully contribute to the success of researchers around the globe working to make precision medicine a reality.”
Advances in genomics have led to valuable insights into disease. Proteomics expands on this research by adding new understandings of complex and dynamic cellular-level processes that can lead to the development of new drugs and diagnostics that have a material impact on human health.
The new Astral analyzer builds on Thermo Fisher’s proven Orbitrap mass spectrometry platform with novel technology to deliver up to two times deeper proteome coverage and up to four times more throughput compared to current mass spectrometers.
“One of the biggest challenges we face studying the human proteome is having too many samples to measure and not enough time,” said Michael MacCoss, professor of genome sciences at the University of Washington. “The Orbitrap Astral mass spectrometer is a true gamechanger, offering an unrivaled combination of sensitivity, dynamic range and speed that doesn’t compromise accurate and precise quantitation. With this instrument, we can deliver on the promise of precision medicine much sooner.”
Thermo Fisher will showcase the Orbitrap Astral mass spectrometer at the American Society for Mass Spectrometry (ASMS) annual conference from June 3-8, 2023, in Houston, Texas, at the George R. Brown Convention Center and at the Hilton Americas-Houston Lanier Grand Ballroom A, B, C. The Orbitrap Astral mass spectrometer together with additional new products being introduced at ASMS create a next generation, end-to-end solution for proteomics that enables the analysis of large cohorts, powering the study of proteomics at a scale previously only obtainable by genomics.
For more information, please visit www.thermofisher.com/ASMS.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230605005016/en/
CONTACT: Media Contact:
Sandy Pound
Thermo Fisher Scientific
Phone: +1 781-622-1223
E-mail:sandy.pound@thermofisher.com
Investor Contact:
Rafael Tejada
Thermo Fisher Scientific
Phone: +1 781-622-1356
E-mail:rafael.tejada@thermofisher.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE OTHER MANUFACTURING FINANCE PROFESSIONAL SERVICES TECHNOLOGY MANUFACTURING OTHER TECHNOLOGY
SOURCE: Thermo Fisher Scientific Inc.
Copyright Business Wire 2023.
PUB: 06/05/2023 08:00 AM/DISC: 06/05/2023 08:01 AM
http://www.businesswire.com/news/home/20230605005016/en
